NASDAQ:PHIO Phio Pharmaceuticals Q4 2025 Earnings Report $1.03 0.00 (0.00%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$1.02 -0.01 (-0.49%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Phio Pharmaceuticals EPS ResultsActual EPS-$0.15Consensus EPS -$0.34Beat/MissBeat by +$0.19One Year Ago EPSN/APhio Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APhio Pharmaceuticals Announcement DetailsQuarterQ4 2025Date3/5/2026TimeBefore Market OpensConference Call DateThursday, March 5, 2026Conference Call Time4:00PM ETUpcoming EarningsPhio Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Annual ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K)Annual report Phio Pharmaceuticals Earnings HeadlinesPhio Pharmaceuticals (NASDAQ:PHIO) Trading 1% Higher - Here's What HappenedSeptember 20 at 6:00 AM | americanbankingnews.comPhio Announces Key PH-762 Milestone with FDA Submission for Next Stage of Cutaneous Squamous Cell CarcinomaSeptember 14, 2026 | markets.businessinsider.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under. | Paradigm Press (Ad)Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell CarcinomaSeptember 14, 2026 | insidermonkey.comPhio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell CarcinomaSeptember 14, 2026 | finance.yahoo.comPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894August 12, 2026 | finanznachrichten.deSee More Phio Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Phio Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phio Pharmaceuticals and other key companies, straight to your email. Email Address About Phio PharmaceuticalsPhio Pharmaceuticals (NASDAQ:PHIO) (NASDAQ: PHIO) is a clinical-stage biotechnology company focused on developing immuno-oncology therapies. The company’s research centers on RNA interference (RNAi), a biological process that can reduce the production of specific proteins involved in disease. Phio is developing treatments intended to activate and enhance the body’s immune response against cancer. The company’s proprietary INTASYL™ platform is designed to deliver small interfering RNA (siRNA) directly into cells without requiring traditional delivery vehicles. Phio has used the platform to develop investigational compounds that target immune-regulating proteins. Its lead program, PH-762, is designed to inhibit PD-1 in immune cells and is being studied as a potential treatment for solid tumors and other cancers. The company has also advanced additional preclinical and clinical-stage programs, including compounds directed at other targets relevant to tumor immunity. Phio Pharmaceuticals was formerly known as RXi Pharmaceuticals and adopted its current name in 2018 to reflect its focus on the INTASYL platform and immuno-oncology. The company is headquartered in Marlborough, Massachusetts, and primarily conducts research and clinical development activities in the United States. Its products remain investigational and are not approved for commercial sale.View Phio Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
